Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma

We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Abidi, Muneer H., Gul, Zartash, Abrams, Judith, Ayash, Lois, Deol, Abhinav, Ventimiglia, Marie, Lum, Lawrence, Mellon-Reppen, Stephanie, Al-Kadhimi, Zaid, Ratanatharathorn, Voravit, Zonder, Jeffrey, Uberti, Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815645/
https://ncbi.nlm.nih.gov/pubmed/22759762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/1973947812Y.0000000004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados